Lynn Miggelbrink
Management of home medications in patients undergoing surgery
Annually, over 200 million people undergo non-cardiac surgery world-
wide. Although non-cardiac surgery is generally safe, today’s surgical
population is older, has multiple comorbidities and polypharmacy is
common. The use of chronic medications may (unexpectedly) influence
postoperative outcomes. However, for many commonly used drugs, it is
not truly known which policy is best around surgery: supplementation
or not, to continuation or discontinuation, and if so, for how long. This
thesis comes forth out of that uncertainty. Its purpose was to better
understand how perioperative management of chronic medications may
influence postoperative recovery and complications.
Part I of this dissertation examines a long-standing clinical dilemma:
should patients on angiotensin-converting-enzyme inhibitors or
angiotensin-II receptor blockers continue these drugs in the perioperative
phase, or should they be discontinued? Continuing them may maintain
cardiovascular stability, whilst withholding may reduce the risk of
intraoperative hypotension and postoperative acute kidney injury (AKI).
For years, there was no definitive evidence to guide clinicians, and
international guidelines differed from one another. This uncertainty led
to the development of the AIPOP trial, a randomized study designed to
compare continuation versus discontinuation of angiotensin-inhibiting
drugs in a broad non-cardiac surgical population. The study protocol
is described in Chapter 2, laying out the design that aimed to answer
this clinical question systematically. Unfortunately, recruitment
challenges resulted in early termination of the study. The results and
lessons learned from this trial are presented in Chapter 3. We found no
difference in the incidence of postoperative AKI between the continuation
and discontinuation groups. However, because the early termination
left the study underpowered, the findings cannot conclusively rule out a
clinically meaningful difference. Instead, they highlight the difficulty of
large-scale perioperative medication trials, and the enduring importance
of collaborative multicenter efforts. In Chapter 4 we investigated
adherence to medication instructions (continuation or discontinuation
of angiotensin inhibitors) before surgery by patients in the AIPOP
trial through measurements of medication levels in blood. Based on
these measurements, half of patients seemed not to have followed the
instructions, especially in the group of patients who received instructions
to discontinue this medication. In light of the results of recent trials that
showed no benefit of discontinuation over continuation of angiotensin
inhibitors, it seems most appropriate to advise patients to continue their
antihypertensive medications before surgery.
In Part II we studied the effect of glucocorticoid supplementation in
patients around surgery. We began by studying surgical patients on
chronic corticosteroid therapy, who therefore are at risk of tertiary
adrenal insufficiency. Because their adrenal gland function may be
suppressed, the normal physiologic stress response to surgery may be
blunted. To prevent adrenal insufficiency, guidelines recommend giving
these patients a perioperative stress-dose of corticosteroids, but in
clinical practice this recommendation is not always followed. In Chapter
5 we found that only 8% of at-risk patients received corticosteroids
according to protocol, while nearly half (48%) received corticosteroids
for other clinical indications. In Chapter 6, we retrospectively examined
whether treatment with corticosteroids affected postoperative symptoms
possibly related to adrenal insufficiency. Compared with control patients,
patients with an indication for a corticosteroid stress-dose given either
an adequate stress dose or a lower corticosteroid dose, did not report
an increase in postoperative symptoms during the first three days.
However, as this was a retrospective study, symptoms may have been
underreported, and subtle endocrine dysregulation may not always
be captured in routine documentation. To strengthen the evidence,
we turned to a prospective approach. In Chapter 7, we performed a
prospective observational cohort study to assess postoperative quality
of recovery in patients at risk for tertiary adrenal insufficiency and in
control patients. An adjusted analysis showed that patients who did not
receive a corticosteroid stress-dose may have impaired postoperative
recovery as compared to patients who did receive such supplementation.
We found no effect of glucocorticoids on recovery in the control group.
This study suggests that stress-dose steroids may help preserve quality
of recovery, a hypothesis that warrants a large, randomized trial.
Chapter 8 explored a different rationale for perioperative corticosteroid
administration: prevention of pulmonary complications in patients with
asthma or COPD undergoing surgery. We found that guideline adherence
was only moderately successful. Anesthesiologists were more likely to
administer corticosteroids in patients with more severe pulmonary
disease, but overall variability remained high. Interviews and practice
pattern analysis revealed several barriers: insufficient patient-specific
detail in the guideline, limited supporting evidence in cases involving
loco-regional anesthesia, and notable differences in how pulmonologists
and anesthesiologists interpret the same recommendations.
In summary, this dissertation tells a larger story: perioperative
management of chronic medication is a critical but under-studied
pillar of perioperative care. Whether the question is (dis)continuing
antihypertensives, supplementing corticosteroids, or aligning specialists
on guidelines to prevent postoperative pulmonary complications, the
evidence gaps remain substantial. The studies in this thesis do not
provide all the answers, but they illuminate where the uncertainties lie,
where practice varies, and where future research should be directed.
Ultimately, the goal remains clear: to enable safer surgery and smoother
recovery for the growing population of multimorbid, medicated patients
who entrust us with their care.
| Publicatiedatum | 8 december 2026 |
| Universiteit | Universiteit Utrecht |
| Auteur | Lynn Miggelbrink |
| ISBN nummer | 978-94-6534-700-4 |